Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gallium Ga 68-NOTA-BBN-RGD
- Development stage
- Unknown
- Lead developer
- National Institute of Biomedical Imaging and Bioengineering
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
Gallium Ga 68-NOTA-BBN-RGD is a radiopharmaceutical agent used as a PET imaging tracer. It is a radioconjugate that combines the bombesin (BBN) fragment BBN(7-14), which targets the gastrin-releasing peptide receptor (GRPR), with an RGD motif that targets integrin αvβ3. Both GRPR and integrin αvβ3 are overexpressed in various tumors, including breast cancer and prostate cancer. The dual-targeting nature of this tracer allows for enhanced tumor detection by binding to both receptors on tumor cells. The compound is labeled with the positron-emitting isotope Gallium-68 via the NOTA chelator for PET imaging applications[1][2][3][5]. It has been primarily investigated for its use in detecting breast cancer and metastatic prostate carcinoma using PET/CT imaging[2][3]. Developed by National Institute For Biomedical Imaging And Bioengineering.
- Other names
- gallium ga 68-nota-bbn7-14-rgdgallium ga-68 nota bbn rgd
02
Targets
GRPR (Gastrin-releasing peptide receptor)αVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on Gallium Ga 68-NOTA-BBN-RGD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gallium Ga 68-NOTA-BBN-RGD.